Burden of Asthma and Role of 2.5 µg Tiotropium Respimat® as an Add-On Therapy: A Systematic Review of Phase 2/3 Trials
Crossref DOI link: https://doi.org/10.1007/s12325-019-01062-w
Published Online: 2019-08-21
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mansfield, Lyndon
Duong-Quy, Sy
Craig, Timothy
Funding for this research was provided by:
Boehringer Ingelheim
Text and Data Mining valid from 2019-08-21
Version of Record valid from 2019-08-21
Article History
Received: 13 June 2019
First Online: 21 August 2019